Literature DB >> 22139830

Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics.

Nicolas Williet1, Claire Pillot, Abderrahim Oussalah, Vincent Billioud, Jean-Baptiste Chevaux, Laurent Bresler, Marc-André Bigard, Jean-Louis Gueant, Laurent Peyrin-Biroulet.   

Abstract

BACKGROUND: The cumulative incidence of colectomy and the impact of 5-aminosalicylates (5-ASA), azathioprine, and antitumor necrosis factor (TNF) treatment on the long-term need for surgery are unknown in ulcerative colitis (UC) in the era of biologics.
METHODS: This was an observational study of a referral center cohort. The cumulative incidence of UC-related colectomy was estimated using the Kaplan-Meier method. Independent predictors of surgery were identified using Cox proportional hazards regression with propensity scores adjustment. The electronic charts of 151 incident cases of UC from Nancy University Hospital, France, diagnosed between 2000 and 2008, were reviewed through January 2010.
RESULTS: The median follow-up time per patient was 58 months. Twenty-one (14%) underwent surgery. The cumulative probabilities of colectomy were respectively 1.3% and 13.5% at 1 and 5 years from the time of diagnosis. The probability of receiving oral mesalamine at 5 years was 68.1%. The corresponding figures were 48.9% for azathioprine and 29.0% for infliximab. For corticosteroids, methotrexate, and cyclosporin these figures were 75%, 8.8%, and 11.5%, respectively. Using multivariate Cox proportional hazards regression analysis after propensity score adjustment, previous use of cyclosporin was the only independent predictor for colectomy (hazard ratio = 4.41; 95% confidence interval 1.75-1.13).
CONCLUSIONS: About one-tenth of patients still require colectomy for UC at 5 years in the era of biologics. Oral 5-ASA, azathioprine, and anti-TNF therapy are not associated with a reduced need for colectomy.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139830     DOI: 10.1002/ibd.21932

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  15 in total

1.  Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan.

Authors:  Hideaki Kimura; Kenichi Takahashi; Kitaro Futami; Hiroki Ikeuchi; Kenji Tatsumi; Kazuhiro Watanabe; Kiyoshi Maeda; Yusuke Watadani; Riichiro Nezu; Hitoshi Kameyama; Sayumi Nakao; Kiyotaka Kurachi; Masayuki Hotokezaka; Koki Otsuka; Toshiaki Watanabe; Heita Ozawa
Journal:  Surg Today       Date:  2015-10-14       Impact factor: 2.549

2.  Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.

Authors:  K T Park; Aaron Sin; May Wu; Dorsey Bass; Jay Bhattacharya
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

3.  Advances in the treatment of ulcerative colitis.

Authors:  Laurent Peyrin-Biroulet
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-12

Review 4.  Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.

Authors:  Neeraj Narula; John K Marshall; Jean-Frederic Colombel; Grigorios I Leontiadis; John G Williams; Zack Muqtadir; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2016-02-09       Impact factor: 10.864

5.  Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.

Authors:  Estelle Fréling; Cédric Baumann; Jean-François Cuny; Marc-André Bigard; Jean-Luc Schmutz; Annick Barbaud; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2015-07-21       Impact factor: 10.864

6.  Weekend hospitalisations and post-operative complications following urgent surgery for ulcerative colitis and Crohn's disease.

Authors:  A N Ananthakrishnan; E L McGinley
Journal:  Aliment Pharmacol Ther       Date:  2013-03-04       Impact factor: 8.171

Review 7.  Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis.

Authors:  Christopher Alexakis; Richard Cg Pollok
Journal:  World J Gastrointest Surg       Date:  2015-12-27

8.  Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.

Authors:  Laurent Peyrin-Biroulet; Julia Salleron; Jérôme Filippi; Catherine Reenaers; Ophélie Antunes; Virginie Filipe; Edouard Louis; Xavier Hébuterne; Xavier Roblin
Journal:  J Crohns Colitis       Date:  2016-01-22       Impact factor: 9.071

9.  Elderly-Onset and Adult-Onset Ulcerative Colitis Are More Similar than Previously Reported in a Nationwide Cohort.

Authors:  Vinayak Kumar; Yash Shah; Dhruvan Patel; Nabeel Khan
Journal:  Dig Dis Sci       Date:  2017-09-07       Impact factor: 3.199

Review 10.  Impact of Modern Drug Therapy on Surgery: Ulcerative Colitis.

Authors:  Florian Kuehn; Richard A Hodin
Journal:  Visc Med       Date:  2018-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.